Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension

Selexipag (Uptravi) is an oral selective IP prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH). The pivotal GRIPHON study was the largest clinical study ever conducted in PAH patients, providing long‐term data from 1,156 patients. PAH comedication did n...

Descripción completa

Detalles Bibliográficos
Autores principales: Krause, A, Machacek, M, Lott, D, Hurst, N, Bruderer, S, Dingemanse, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529739/
https://www.ncbi.nlm.nih.gov/pubmed/28556581
http://dx.doi.org/10.1002/psp4.12202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529739/
https://www.ncbi.nlm.nih.gov/pubmed/28556581
http://dx.doi.org/10.1002/psp4.12202

Ejemplares similares